CAPS Medical

CAPS Medical is a clinical-stage MedTech company developing PlasmaSureTM, a first-in-class non-thermal plasma therapy for the selective, minimally invasive treatment of solid tumors, including bladder, GI, esophageal, lung, and prostate cancers. The platform is compatible with existing endoscopic and robotic systems, enabling seamless integration into current clinical workflows. PlasmaSureTM has received FDA Breakthrough Device Designation for non-muscle invasive bladder cancer (NMIBC), supporting prioritized FDA engagement and an accelerated regulatory pathway. CAPS is now incorporated in the U.S., strengthening alignment with U.S. clinical, regulatory, and strategic partners.